Contact
searchSearch
HMP Global

Multiple Myeloma Topic Center

Featured Article

News
Teclistamab Shows Comparable Efficacy but Lower Costs Than Elranatamab in RRMM Study
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
Real-World Elranatamab in RRMM Falls Short on Durability Despite Strong Initial Responses
04/17/2026
Rebecca Amrick
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising...
04/17/2026
First Report Managed Care
News
Outpatient Cilta-cel Shows Promise in Multiple Myeloma, With Early Signs of Lower Costs and Comparable Outcomes
04/09/2026
Rebecca Amrick
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review...
04/09/2026
First Report Managed Care
News
Higher Health Care Burden in Multiple Myeloma With Extramedullary Disease, Study Finds
12/02/2025
Grace Taylor, MS, MA
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd...
12/02/2025
First Report Managed Care
News
High Health Care Costs Persist for Relapsed/Refractory Multiple Myeloma in the US
11/17/2025
Grace Taylor, MS, MA
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that...
11/17/2025
First Report Managed Care
News
Daratumumab Quadruplet Improves Depth of Response in Older Myeloma
11/10/2025
Hannah Musick
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN...
11/10/2025
First Report Managed Care
Jagannath
CONFERENCE COVERAGE
The Path to Cure in Multiple Myeloma: How Emerging Therapies Are Changing the Landscape
10/17/2025
Sundar Jagannath, MBBS
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath,...
10/17/2025
First Report Managed Care
News
Patients and Clinicians Prioritize Scientific Innovation and Treatment-Free Living in Multiple Myeloma Care
10/10/2025
Hannah Musick
Both patients and providers ranked progression-free survival as the most important treatment attribute in multiple myeloma, but also strongly valued the ability to live without ongoing treatment and the presence of scientific innovation.
Both patients and providers ranked progression-free survival as the most important treatment attribute in multiple myeloma, but also strongly valued the ability to live without ongoing treatment and the presence of scientific innovation.
Both patients and providers...
10/10/2025
First Report Managed Care
Lonial
CONFERENCE COVERAGE
SOHO 2025 Highlights: Redefining Risk and Treatment in Smoldering Multiple Myeloma
10/10/2025
Sagar Lonial, MD
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his...
10/10/2025
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
Usmani Headshot
Conference Coverage
Rethinking the Risk: Evolving Strategies for High-Risk Smoldering Myeloma at SOHO 2025
09/08/2025
Saad Z. Usmani, MD, FACP
Dr Saad Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, explores the evolving debate on early intervention for high-risk smoldering multiple myeloma, highlighting pivotal trial data and its potential to reshape...
Dr Saad Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, explores the evolving debate on early intervention for high-risk smoldering multiple myeloma, highlighting pivotal trial data and its potential to reshape...
Dr Saad Usmani, chief of the...
09/08/2025
First Report Managed Care

Newsfeed

News
Teclistamab Shows Comparable Efficacy but Lower Costs Than Elranatamab in RRMM Study
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
Real-World Elranatamab in RRMM Falls Short on Durability Despite Strong Initial Responses
04/17/2026
Rebecca Amrick
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising...
04/17/2026
First Report Managed Care
News
Outpatient Cilta-cel Shows Promise in Multiple Myeloma, With Early Signs of Lower Costs and Comparable Outcomes
04/09/2026
Rebecca Amrick
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review suggests that outpatient administration of ciltacabtagene autoleucel, or cilta-cel, may be a feasible option for selected patients with relapsed or refractory multiple myeloma, potentially reducing hospital...
A systematic literature review...
04/09/2026
First Report Managed Care
News
Higher Health Care Burden in Multiple Myeloma With Extramedullary Disease, Study Finds
12/02/2025
Grace Taylor, MS, MA
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd International Myeloma Society (IMS) Annual Meeting shows that extramedullary disease significantly increases health care utilization and costs for patients with triple-class–exposed (TCE) relapsed/refractory...
A study presented at the 22nd...
12/02/2025
First Report Managed Care
News
High Health Care Costs Persist for Relapsed/Refractory Multiple Myeloma in the US
11/17/2025
Grace Taylor, MS, MA
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that patients with relapsed or refractory multiple myeloma (RRMM) who discontinue lenalidomide face overwhelming monthly health care costs driven primarily by drug and infusion expenses.
A US claims study reveals that...
11/17/2025
First Report Managed Care
News
Daratumumab Quadruplet Improves Depth of Response in Older Myeloma
11/10/2025
Hannah Musick
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN and PERSEUS, transplant-eligible adults aged ≥65 years with newly diagnosed multiple myeloma who received daratumumab-VRd followed by D-R achieved deeper responses and higher MRD-negativity with a trend toward...
In a pooled analysis of GRIFFIN...
11/10/2025
First Report Managed Care
News
Patients and Clinicians Prioritize Scientific Innovation and Treatment-Free Living in Multiple Myeloma Care
10/10/2025
Hannah Musick
Both patients and providers ranked progression-free survival as the most important treatment attribute in multiple myeloma, but also strongly valued the ability to live without ongoing treatment and the presence of scientific innovation.
Both patients and providers ranked progression-free survival as the most important treatment attribute in multiple myeloma, but also strongly valued the ability to live without ongoing treatment and the presence of scientific innovation.
Both patients and providers...
10/10/2025
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
DKRd Induction Yields Superior MRD Negativity in NDMM, Regardless of Transplant
07/23/2025
Grace Taylor, MS, MA
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that...
07/23/2025
First Report Managed Care
News
Peripheral Residual Disease Monitoring Signals Progression Risk in Multiple Myeloma
10/18/2024
Jolynn Tumolo
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease...
10/18/2024
First Report Managed Care
News
IMC Care Matches ICU Outcomes for Hypertensive Emergencies, Study Finds
05/04/2026
Rebecca Amrick
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with hypertensive emergencies had similar outcomes in intermediate care (IMC) and intensive care unit (ICU) settings, suggesting IMC units may safely reduce ICU utilization without compromising care.
In a recent study, patients with...
05/04/2026
First Report Managed Care
News
Adjuvant Immunotherapy Costs Challenge Lung Cancer Affordability
05/04/2026
Hannah Musick
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may...
05/04/2026
First Report Managed Care
News
Teclistamab Shows Comparable Efficacy but Lower Costs Than Elranatamab in RRMM Study
05/04/2026
Rebecca Amrick
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but consistently lower costs, teclistamab may offer a more economically favorable option than elranatamab for patients with relapsed or refractory multiple myeloma (RRMM), according to a study published in the...
With similar response rates but...
05/04/2026
First Report Managed Care
News
Glofitamab Emerges as an Accessible, High-Potential Alternative to CAR T Therapy in DLBCL
04/29/2026
Rebecca Amrick
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood Cancers Today explains how the bispecific antibody glofitamab may offer a more accessible and potentially curative alternative to chimeric antigen receptor (CAR) T-cell therapy for patients with diffuse large...
Dr Tycel Phillips from Blood...
04/29/2026
First Report Managed Care
News
Hemodialysis Triggers Wide Epigenetic Changes in Patients With Chronic Kidney Disease
04/27/2026
Rebecca Amrick
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study analyzed the impact of hemodialysis on DNA methylation patterns and found inflammation to be linked a system-wide reaction.
A small-scale exploratory study...
04/27/2026
First Report Managed Care
News
Sequencing of Bispecific Antibodies May Influence Outcomes in R/R Follicular Lymphoma
04/24/2026
Rebecca Amrick
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study suggests bispecific antibodies remain effective in relapsed or refractory follicular lymphoma (R/R FL), but treatment sequencing may impact progression-free survival.
A real-world multicenter study...
04/24/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Semaglutide Shows Health Benefits for CVD but Falls Short on Cost-Effectiveness at Current Drug Prices
04/23/2026
Rebecca Amrick
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that...
04/23/2026
First Report Managed Care
Behind the Bill
DOJ Places FDA-Approved Marijuana Products in Schedule III
04/23/2026
Grace Taylor, MS, MA
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice...
04/23/2026
First Report Managed Care

Insights

Jagannath
CONFERENCE COVERAGE
The Path to Cure in Multiple Myeloma: How Emerging Therapies Are Changing the Landscape
10/17/2025
Sundar Jagannath, MBBS
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath, MBBS, joined Noopur Raje, MD, Krina Patel, MD, and other experts to discuss groundbreaking advances in CAR T-cell, bispecific, and trispecific therapies that are transforming multiple myeloma from a chronic...
At SOHO 2025, Sundar Jagannath,...
10/17/2025
First Report Managed Care
Lonial
CONFERENCE COVERAGE
SOHO 2025 Highlights: Redefining Risk and Treatment in Smoldering Multiple Myeloma
10/10/2025
Sagar Lonial, MD
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his SOHO 2025 case presentation on evolving definitions of high-risk smoldering multiple myeloma, the growing evidence for early intervention, and how innovations such as CAR T-cell therapies and bispecific...
Dr Sagar Lonial discusses his...
10/10/2025
First Report Managed Care
Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Maria Asimopoulos
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
Headshot of Joshua Richter, MD, Mount Sinai
Interview
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Maria Asimopoulos
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate...
10/18/2022
First Report Managed Care

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use